Stockscreener 앱 받기
10.38
2.27%
0.23
시간 외 거래:
10.38
전일 마감가:
$10.15
열려 있는:
$10.12
하루 거래량:
548.44K
Relative Volume:
0.58
시가총액:
$1.10B
수익:
$247.00M
순이익/손실:
$-249.00M
주가수익비율:
-3.3592
EPS:
-3.09
순현금흐름:
$-267.00M
1주 성능:
+3.18%
1개월 성능:
+1.47%
6개월 성능:
+2.37%
1년 성능:
-42.11%
1일 변동 폭
$10.07
$10.39
1주일 범위
$9.92
$11.00
52주 변동 폭
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
명칭
Arcus Biosciences Inc
전화
(510) 694-6200
주소
3928 POINT EDEN WAY, HAYWARD, CA
RCUS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
10.38 | 1.11B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.18 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.65 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.20 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
708.09 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.91 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-26 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | 개시 | H.C. Wainwright | Neutral |
| 2024-10-08 | 개시 | Wells Fargo | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-24 | 개시 | Berenberg | Buy |
| 2020-11-23 | 개시 | Evercore ISI | Outperform |
| 2020-04-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-09-27 | 개시 | Mizuho | Buy |
| 2019-05-24 | 재개 | Citigroup | Buy |
| 2018-10-09 | 개시 | Wedbush | Outperform |
| 2018-04-09 | 개시 | Citigroup | Buy |
| 2018-04-09 | 개시 | Goldman | Neutral |
| 2018-04-09 | 개시 | Leerink Partners | Outperform |
모두보기
Arcus Biosciences Inc 주식(RCUS)의 최신 뉴스
Clinical-Stage Biotech Arcus Lines Up Citi, Morgan Stanley, and H.C. Wainwright September Conferences - Stock Titan
Mizuho raises Arcus Biosciences stock price target on casdatifan potential By Investing.com - Investing.com Canada
Will Arcus Biosciences Inc. Sustain Its Chart BreakoutGDP Growth & Fast Gain Swing Trade Alerts - classian.co.kr
Will Arcus Biosciences Inc. benefit from rate cutsWeekly Investment Summary & Reliable Breakout Stock Forecasts - thegnnews.com
Arcus Biosciences Inc. Stock Recovery Path — Analyst Breakdown2025 Earnings Impact & Community Consensus Picks - 선데이타임즈
Watch for Bullish Crossover in Arcus Biosciences Inc.Portfolio Value Summary & High Accuracy Swing Entry Alerts - sundaytimes.kr
Jim Cramer on Arcus Biosciences: “Let This Be Your Speculation” - MSN
Wyckoff Accumulation Phase Possible in Arcus Biosciences Inc.Earnings Performance Report & Daily Technical Forecast Reports - newsyoung.net
Candlestick signals on Arcus Biosciences Inc. stock today2025 Market Outlook & Momentum Based Trading Signals - Newser
Using RSI to spot recovery in Arcus Biosciences Inc.Gap Down & Weekly High Potential Alerts - Newser
Identifying reversal signals in Arcus Biosciences Inc.July 2025 PostEarnings & AI Based Buy/Sell Signal Reports - Newser
Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2 - MSN
Will breakout in Arcus Biosciences Inc. lead to full recoveryQuarterly Trade Summary & Fast Entry High Yield Tips - Newser
Arcus Biosciences’ SWOT analysis: stock’s potential hinges on HIF-2alpha data - Investing.com
Jim Cramer Recommends Uranium Energy Corp., Warns Against Overreliance on Arcus Biosciences. - AInvest
Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus - Benzinga
What machine learning models say about Arcus Biosciences Inc.Weekly Profit Report & Expert Approved Trade Ideas - Newser
Why Arcus Biosciences Inc. stock attracts strong analyst attentionWeekly Trade Analysis & Fast Moving Stock Trade Plans - Newser
New Product Launches: Will They Boost Arcus Biosciences Inc. Stock in 2025July 2025 Big Picture & Real-Time Chart Breakout Alerts - Newser
What institutional flow reveals about Arcus Biosciences Inc.Earnings Growth Report & Risk Managed Investment Entry Signals - Newser
Will Arcus Biosciences Inc. Hold Gains Into CloseReliable Alerts for Daily Stock Movers Released - beatles.ru
Arcus Biosciences (NYSE:RCUS) Upgraded at Wall Street Zen - Defense World
How to escape a deep drawdown in Arcus Biosciences Inc.Free Smart Trade Plans With Risk Protection - Newser
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Cantor Fitzgerald Issues Positive Forecast for RCUS Earnings - Defense World
Wedbush Forecasts Lower Earnings for Arcus Biosciences - Defense World
Q3 EPS Forecast for Arcus Biosciences Reduced by Analyst - Defense World
Custom watchlist performance reports with Arcus Biosciences Inc.AI Volatility Forecast and Risk Monitor - Newser
Arcus Biosciences Q2 Earnings and Catalysts Ahead: A Risky Buy for 12 Months - AInvest
Arcus BiosciencesA Risky Buy Ahead Of Pivotal, Catalyst Rich 12 Months (NYSE:RCUS) - Seeking Alpha
Trapped Investors in Arcus Biosciences Inc. Await Breakout SignalNews Based Entry Opportunity Alerts Detected - beatles.ru
Arcus Biosciences, Inc. (NYSE:RCUS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Zurcher Kantonalbank Zurich Cantonalbank Buys 2,524 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Gilead and Arcus Advance Promising Colorectal Cancer Study - TipRanks
Arcus Biosciences Tops Revenue Forecasts And Drives Pipeline Growth - Finimize
Gilead and Arcus Biosciences’ Promising Study on Advanced Gastrointestinal Cancers - TipRanks
A Quick Look at Today's Ratings for Arcus Biosciences(RCUS.US), With a Forecast Between $14 to $52 - 富途牛牛
Wells Fargo Adjusts Price Target for Arcus Biosciences (RCUS) | - GuruFocus
H.C. Wainwright Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Morgan Stanley Lifts Price Target on Arcus Biosciences to $23 From $22, Keeps Overweight Rating - MarketScreener
Arcus Biosciences (RCUS) Surges 10% on Q2 Earnings Beat and Pipeline Momentum - AInvest
Decoding Arcus Biosciences Inc (RCUS): A Strategic SWOT Insight - GuruFocus
Arcus Biosciences Reports Strong Q2 2025 Results - TipRanks
Arcus Biosciences earnings beat by $0.01, revenue topped estimates - Investing.com Canada
Arcus Biosciences Q2 revenue beats analyst expectations - MarketScreener
Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update - Stock Titan
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Is Arcus Biosciences (NYSE:RCUS) Using Debt In A Risky Way? - 富途牛牛
When is Arcus Biosciences Inc. stock expected to show significant growthIdentify undervalued stocks ready to soar - Jammu Links News
How volatile is Arcus Biosciences Inc. stock compared to the marketTremendous gains - Jammu Links News
What are the technical indicators suggesting about Arcus Biosciences Inc.Free Wealth Planning Blueprint - Jammu Links News
Arcus Biosciences Inc (RCUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Arcus Biosciences Inc 주식 (RCUS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ROSEN TERRY J | Chief Executive Officer |
Feb 27 '25 |
Buy |
10.18 |
19,800 |
201,465 |
2,554,160 |
| GILEAD SCIENCES, INC. | 10% Owner |
Feb 18 '25 |
Buy |
11.00 |
1,363,636 |
14,999,996 |
31,424,760 |
| Goeltz II Robert C. | Chief Financial Officer |
Dec 31 '24 |
Sale |
15.00 |
3,594 |
53,910 |
60,138 |
0.95%
0.90%
자본화:
|
볼륨(24시간):